4月8日,据外媒报道,细胞分析公司Celcuity宣布与辉瑞公司达成全球许可协议,辉瑞将gedatolisib(一种1b期pan-PI3K / mTOR抑制剂)专有权授予给Celcuity。Gedatolisib正在临床开发中,用于治疗ER + / HER2-阴性的晚期或转移性乳腺癌患者。
根据许可协议条款,辉瑞向Celcuity提...查看全文
美股 美股开盘 | 三大指数涨跌不一,搜狐(SOHU.US)涨超13% 2021年4月9日 20:31:45 智通财经APP获悉,4月9日(周五)美股开盘,三大指数涨跌不一。截至发稿,道指涨0.18%,标普500指数跌0.03%,纳指跌0.41%。 个股消息 细胞分析公司Celcuit... 网页链接
格隆汇4月9日丨Celcuity(CELC.US)盘前大涨38.78%报19.86美元。公司周四表示,已与辉瑞公司签署了一项全球许可协议,获得了开发和商业化辉瑞Gedatolisib的全球许可。Gedatolisib正处于临床开发阶段,用于治疗某些类型的乳腺癌患者。Celcuity表示:“来自103... 网页链接
$Celcuity(CELC)$ DEF 14A Other definitive proxy statements Accession Number: 0001493152-24-011792 Act: 34 Size: 1 MB 网页链接
$Celcuity(CELC)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001493152-24-011794 Act: 34 Size: 715 KB 网页链接
$Celcuity(CELC)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001493152-24-011549 Act: 34 Size: 7 MB 网页链接
$Celcuity(CELC)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001493152-24-011514 Act: 34 Size: 338 KB 网页链接
$Celcuity(CELC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-006878 Size: 33 KB 网页链接
$Celcuity(CELC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-004281 Size: 11 KB 网页链接
$Celcuity(CELC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-003329 Size: 25 KB 网页链接
$Celcuity(CELC)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001062993-24-003326 Size: 25 KB 网页链接
$Celcuity(CELC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-024203 Act: 34 Size: 221 KB 网页链接
$Celcuity(CELC)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001104659-24-024012 Act: 34 Size: 90 KB 网页链接